Viruses, Vol. 12, Pages 125: Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice
In this study, we compared the immunological efficacy of the vaccine candidates in BALB/c mice in terms of the levels of humoral and cellular immune responses. The results show that the rabies virus vector-based vaccine can induce remarkably earlier antibody response and higher levels of cellular immunity than the GEM particles vector. However, the GEM particles vector-based vaccine candidate can induce remarkably higher antibody response, even at a very low dose of 1 µg. These results indicate that vaccines constructed using different vaccine vector platforms for the same pathogen have different rates and trends in humoral and cellular immune responses in the same animal model. This discovery not only provides more alternative vaccine development platforms for MERS-CoV vaccine development, but also provides a theoretical basis for our future selection of vaccine vector platforms for other specific pathogens.
The name of the new coronavirus that first appeared in China has been evolving to its now official designation: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).Medscape Medical News
PMID: 32089242 [PubMed - in process]
People told to brace for potentially ‘severe’ disruptions as Democrats question readiness
A summary of key findings of the largest case series to date has been published.Medscape Medical News
For the past month, Vir Biotechnology Inc. said it was working on ways to address the coronavirus epidemic that has killed 3,000 people since December. It made good on that promise Tuesday, inking a deal with Shanghai's WuXi Biologics. Financial terms of the development, manufacturing and commercialization collaboration centering on human monoclonal antibodies against the Covid-19 coronavirus were not disclosed by San Francisco-based Vir (NASDAQ: VIR). The deal emerges as the National Institute…
Officials with the Atlanta-based Centers of Disease Control and Prevention say spread of the coronavirus in the U.S. is not a question of "if," but "when." Dr. Nancy Messonnier, the CDC's director of the National Center for Immunization and Respiratory Diseases, said the virus, called COVID-19, is "rapidly evolving and spreading" and that "successful containment at U.S. borders is becoming problematic." Community spread of the virus, which began i ts spread in China, have been reported in Hong…
The latest tally of novel coronavirus cases in the United States has jumped to 57, according to the Centers for Disease Control and Prevention, as one of the agency's top officials warned Tuesday that health experts expect to see the virus spread.
Covid-19 will become a pandemic. We don't yet know how severe it will be, nor do we know if the virus will spread to all continents, but it's already spreading widely in China, South Korea, Italy, Iran and elsewhere -- and thousands of undetected and infectious patients have been and continue to travel around the world.
Clusters of infection are likely in American communities, health officials said. Some lawmakers questioned whether the nation is prepared.
Iran's coronavirus death toll rose to 16 on Tuesday, the highest outside China, increasing its international isolation as dozens of countries from South Korea to Italy accelerated emergency measures to curb the epidemic's global spread.